--- title: "Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start?" type: "News" locale: "en" url: "https://longbridge.com/en/news/285906519.md" description: "Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The highest price reached HKD 191.8, while the lowest dipped to HKD 183.3, ultimately closing with a slight decline of 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, with phase buying pressure building up again. The total trading volume reached HKD 748 million, maintaining an active range as a leading stock in the biotechnology sector, with sustained investor interest. On the news front, the global biotechnology sector has recently gained continuous attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines such as PD-1 and BTK inhibitors are expected to see significant growth in overseas markets, which remains an important logic for institutional investment. Additionally, the Hong Kong stock market has recently benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained stable near the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume continues to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue" datetime: "2026-05-12T01:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285906519.md) - [en](https://longbridge.com/en/news/285906519.md) - [zh-HK](https://longbridge.com/zh-HK/news/285906519.md) --- # Pre-market trend | BeOne Medicines (6160.HK) 5/11 bulls accumulate and close flat, is a new round of rally about to start? Yesterday's closing price for BeOne Medicines was HKD 190.5, with an intraday volatility of over 4%. The stock reached a high of HKD 191.8 and a low of HKD 183.3, ultimately closing slightly down by 0.05%. The MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is re-accumulating in the previous upward trend, and phase buying is being rebuilt. The total trading volume reached HKD 748 million, maintaining an active level for this leading biotechnology stock, with continuous attention from funds. On the news front, the global biotechnology sector has recently gained sustained attention. As one of the most internationalized Chinese innovative pharmaceutical companies, BeOne Medicines' core pipelines, such as PD-1 and BTK inhibitors, are still an important logic for institutional layout due to expectations of volume growth in overseas markets. Additionally, the Hong Kong stock market has benefited from expectations of diplomatic interactions between the U.S. and China—U.S. President Trump is scheduled to visit China from May 13 to 15, which the market interprets as a temporary easing of U.S.-China relations, likely reducing geopolitical uncertainties in the biopharmaceutical field and providing positive catalysts for companies like BeOne Medicines that have significant business in the U.S. From a technical perspective, BeOne Medicines' current stock price is operating near the 5-day and 10-day moving averages, with the short-term moving average system maintaining a bullish arrangement. Although there was significant volatility during the day, the final closing price remained close to the opening price, indicating a temporary balance between bullish and bearish forces. After confirming the golden cross above the MACD zero axis, if the trading volume can continue to stay above HKD 600 million in the following trading days, the momentum to test previous highs is expected to continue. In terms of sector linkage, the overall trading of the Hong Kong pharmaceutical sector is active, with peers like WuXi Biologics and CanSino Biologics also maintaining high-level operations. The risk to watch is that the stock price is already in a relatively high range, with noticeable short-term profit accumulation. If the trading volume shrinks or if there is a systemic correction in the external market, the probability of phase oscillation and washout will increase. Overall, the bullish technical pattern has not been broken, and the news front provides positive support. The short-term trend is biased towards bullish but requires close attention to volume coordination. _This article only provides technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances._ ### Related Stocks - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [02269.HK](https://longbridge.com/en/quote/02269.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md) ## Related News & Research - [BeOne Medicines Ltd (6160) Gets a Buy from CMBC International](https://longbridge.com/en/news/285886964.md) - [Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)](https://longbridge.com/en/news/285667787.md) - [2 Ways to Play the Big Pharma Patent Cliff](https://longbridge.com/en/news/286553222.md) - [BeOne Medicines Highlights Global Footprint With Latest Form 10-Q Filing](https://longbridge.com/en/news/285368026.md) - [20:00 ETLOTTE Biologics Expands Antibody Manufacturing Agreement with Ottimo Pharma](https://longbridge.com/en/news/286687690.md)